A checklist for suitability of biomarkers as surrogate endpoints in chemoprevention of breast cancer.
By reference to a "checklist" of requirements for substances or processes to qualify as surrogate endpoint biomarkers, both malignin and antimalignin antibody are found to be suitable for use in breast cancer chemoprevention trials. Antimalignin has been shown to be highly specific and sensitive, modulatable and reversible, detectable early in appearance of malignancy and upon recovery therefrom, and differentially expressed in high-risk individuals as compared with the general population.
Bogoch
S
S
Foundation for Research on the Nervous System, Boston, MA 02215.
Bogoch
E S
ES
D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000032:analysis; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000097:blood / Q000473:pathology* / Q000517:prevention & control*; D002272:Carcinoembryonic Antigen / Q000097:blood; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D009363:Neoplasm Proteins / Q000032:analysis* / Q000276:immunology; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic; D012016:Reference Values
D016588:Anticarcinogenic Agents; D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D001323:Autoantibodies; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D009363:Neoplasm Proteins; C016548:malignin